SPOTLIGHT: Rituxan falls short in lupus trial


In a big disappointment for Genentech and Biogen Idec, Rituxan failed its late-stage test against lupus. Already approved for non-Hodgkins lymphoma and rheumatoid arthritis treatment, Rituxan might have added $1 billion to its $2.3 billion in 2007 sales with a lupus indication. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.